Cutia Therapeutics (02487.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

Market Cap

HKD 641.87M

MomentumView details →

1D Return

+0.57%

YTD Return

−61.23%

RSI (14)

28.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

Market Cap

HKD 641.87M

RSI (14)

28.6

MomentumView details →

1D Return

+0.57%

YTD Return

−61.23%

ProfitabilityView details →

Gross Margin

55.09%

Net Margin

−125.70%

EBITDA Margin

−115.67%

ROE (TTM)

−87.39%

ROA (TTM)

−59.23%

Asset Turnover

0.51x

GrowthView details →

Revenue YoY

+313.30%

EPS YoY

+89.64%

FCF YoY

+3.01%

Revenue CAGR 3Y

+209.25%

EPS CAGR 3Y

+26.95%

EBITDA YoY

+31.78%

EarningsView details →

EPS (Actual)

−HKD 0.58

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

−82.70%

Capital & dividendView details →

Debt/Equity

0.36x

Current Ratio

3.87x

Quick Ratio

3.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

615.77M

Net Income (TTM)

−774.00M

Op. CF (TTM)

−749.18M

Next earningsMar 30, 2027 →

Latest newsMore news →

Cutia's Biologics License Application for CU-20101 was accepted for review by China's National Medical Products Administration.2d ago

Cutia Group reported interim results for the six months ended June 2026, with revenue of RMB 62.71 million, down 5.4% year-on-year, and a narrowed net loss of RMB 180 million compared to RMB 239 million in the prior-year period.4d ago

Similar companies

MapLight Therapeutics, Inc.MPLT Contineum Therapeutics, Inc. Class A Common StockCTNM Wuhan YZY Biopharma Co Ltd02496.HK OmniAb, Inc.OABI Altimmune, Inc.ALT Bright Minds Biosciences Inc.DRUG Find similar companies →

Latest newsMore news →

Cutia's Biologics License Application for CU-20101 was accepted for review by China's National Medical Products Administration.2d ago Cutia Group reported interim results for the six months ended June 2026, with revenue of RMB 62.71 million, down 5.4% year-on-year, and a narrowed net loss of RMB 180 million compared to RMB 239 million in the prior-year period.4d ago